Condition: Advanced Solid Tumors · Sponsor: Abalos Therapeutics GmbH
This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical activity of ABX-001 administered intravenously (IV) alone (Part A) or co-administered with pembrolizumab (Part B) in participants with refractory/relapsed advanced solid tumors.
This description comes directly from the study's public registry record.
Thomas Bogenrieder, Chief Medical Officer, MD, PhD · +49 173162 2682 · bogenrieder@abalos-tx.com
Always discuss trial participation with your own doctor first.
| Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF) | Berlin, Germany | Recruiting |
| Universitaetsklinikum Tuebingen | Tübingen, Germany | Recruiting |
| Vall d'Hebron Institut d'Oncologia | Barcelona, Spain | Recruiting |
| Hospital Universitario Fundacion Jimenez Diaz | Madrid, Spain | Recruiting |
| The START Center for Cancer Care - CIOCC | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231458